Comparative Pharmacology
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus XCOPRI.
FOSPHENYTOIN SODIUM vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a water-soluble prodrug of phenytoin. It is converted to phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials and reducing seizure propagation.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
Loading dose: 15-20 mg PE/kg IV at 100-150 mg PE/min; maintenance: 4-6 mg PE/kg/day IV divided every 8-12 hours.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin is approximately 15 minutes (range 8-30 minutes) following IV administration; however, the half-life of the active metabolite phenytoin is 20-30 hours (dose-dependent) in adults, requiring careful monitoring for accumulation.
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Renal excretion of inactive metabolites (primarily fosphenytoin metabolites including phenytoin metabolites) accounts for approximately 80-90% of elimination; less than 5% excreted unchanged in urine; biliary/fecal excretion minimal.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category D/X
Category C
Anticonvulsant
Anticonvulsant